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Previous studies in this laboratory have demon-
strated a delay in the elimination of lipids from
the blood stream of hyperlipemic patients after
intravenous fat infusion (1). These studies sug-
gested a defect in the lipemia clearing mecha-
nism in hyperlipemia. We subsequently found
(2) that the serum of patients with hyperlipemia
(primary and secondary to diabetes, nephrosis,
glycogen storage disease) inhibited the heparin-
induced lipemia clearing activity of normal serum.
It was further found that the inhibitory activi-
ties of hyperlipemic serum were associated with
the supernatant fatty layer obtained after high-
speed centrifugation (3). Similar inbibitory ac-
tivities as in hyperlipemic serum are present in
human and other mammalian tissue (4). Since
normal human and other mammalian tissue, like
hyperlipemic serum, inhibit a number of lipase
preparations as well as heparin-induced lipemia
clearing activity (5, 6), they can be considered to
have general antilipolytie action (7, 8, 9).
In our studies of the antilipolytic action of
hyperlipemic serum, we found that intravenous
heparin produced less clearing activity in pa-
tients with hyperlipemia than in normal indi-
viduals (2). These studies were extended and are
reported here.
METHODS AND MATERIALS
Heparint (0.7 mg/kg. of body weight) was
administered by intravenous injection to 6 pa-
tients With idiopathic hyperlipemia and 3 individ-
uals without known disturbance of lipid transport.
All subjects had been fasting for at least 12 hours.
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During the course of the study (24 hours) they
were on a fat-free diet. Blood samples were taken
immediately prior to and at regular intervals after
the administration of heparin. The blood samples
were centrifuged at 3,000 g for 30 minutes at 5°C.
The supernatant plasma was stored at 5°C. until
it was tested.
In order to determine whether a relationship
exists between the blond lipid levels and the anti-
lipolytic action of serum, the same patients re-
ceived 200 cc. of 10 per cent cream orally after
they had fasted for 12 hours. For the duration of
these studies (24 hours) a fat-free diet was offered.
Blood samples were collected prior to the intake
of cream and at regular intervals thereafter. The
samples were processed as described before.
The optical density of the serum was determined
by the method of Geyer et at. (10). The total fatty
acids (11), the phnspholipids (12), and the total
cholesterol and cholesterol esters (13) were meas-
ured. From these data the neutral fat levels were
calculated.
Clearing activity and its inhibition were deter-
mined as previously reported (2) in a mixture
containing 0.6 cc. of normal human postheparin
serum,t 0.6 cc. of the sample of serum to be tested,
and 0.3 cc. of a standard fat emulsionj This mix-
ture was incubated at 37°C. Spectrophotometric
determinations were carried out at 5- to 19-minute
intervals according to a modification (2) of the
method of Grossman (14). The electrophoretic
mobilities of the alpha and beta lipnproteins were
determined as described by Herbst, Lever and
Hurley (15). The evolution of glycerol was meas-
ured by Korn's modification (16) of the method of
t Postheparin serum was prepared as previously
described (2). It was defibrinated by the addition
of thrombin (topical thrombin, Parke, Davis and
Co., Detroit, Michigan), 1 cc. of physiological
saline containing 1,000 units of thrombin to 20 cc.
of serum. The clot was discarded after the fluid
had been expressed from it. This procedure, which
does not affect the clearing activity of the serum,
eliminates the formation of clots which interfere
with the spectrophotometric determinations.§ The standard fat emulsion contained 15 per
cent coconut oil, 0.5 per cent pluronic (a nonionic
detergent) and 1 per cent polyglycerol oleate. It
was generously supplied by Dr. C. Meyer, Dept.
of Clinical Investigation, Medical Dlv., UpjohnCo., Kalamazoo, Mich. It was diluted 30 times
for use in these experiments.
Lambert and Neish (17); the unmodified method
of Lambert and Neish (17) was also used.
RESULTS
Clearing activity following heparin adminis-
tration appeared considerably later and was less
pronounced in the serum of patients with hyper-
lipemia than in normal individuals (Figure 1).
Maximum clearing activity was present in nor-
mal individuals within 30 minutes of hcparin
administration and began to decrease after 2
hours, fell rapidly during the next 3 to 5 hours,
and from then on disappeared more gradually
over the next 12 to 16 hours. In hyperlipemic pa-
tients clearing activity was not noted until 1
hour after the injection, at a time when maxi-
mum activity had already been attained in
normal serum. The maximum clearing activity
in hyperlipemic patients was markedly less than
that found in normal individuals and did not
appear until 3 to 4 hours after heparin injection
(i.e., the time at which the clearing activity in
normal individuals had begun to decrease).
The rate of electrophoretic migration of the
alpha and beta lipoproteins of normal as well as
of hyperlipemic serum began to increase within
15 minutes after the administration of heparin.
In the hyperlipemic subjects this increase con-
tinued until their clearing activity reached maxi-
mum levels and was maintained for 2 to 4 hours
while clearing activity was already declining.
This phenomenon was similar to that observed
in normal individuals with the exception that
maximum rates of electrophoretic migration
were reached earlier than in hyperlipemic pa-
tients. Glycerol levels (in normal and hyper-
lipemic sera obtained at various intervals after
heparin injection) also paralleled the levels of
their respective clearing activities.
Turbidity Measurements. As the blood level of
clearing activity increased, the turbidity of the
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Fm. 1. Development of lipemia clearing activity in the plasma of normal and hyperlipemic subjects
following intravenous administration of heparin.
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FIG. 2. Turbidity changes in the plasma of
normal (lipemie phase) and hyperlipemic in-
dividuals following intravenous administration of
heparin.
A, B,—hyperlipemie subjects; C,—normal sub-ject.
DEFECTIVE LIPEMIA CLEARING RESPONSE TO HEPARIN 93
FIG. 3.
heparin.
mg. NEUTRAL FAT
700
Changes in the plasma
TIME (HOURS)
levels of neutral fat following the intravenous administration of
— TOTAL CHOLESTEROL
CHOLESTEROL ESTERS
ITi3:EE
300
NORMAL
___________
—x
i—
NORMAL'
0 I I I I0 I 2 3 4 5 6 7 8 9 10
TIME (HOURS) AFTER /LV. HEPARIN
FIG. 4. Changes in the plasma levels of cholesterol and cholesterol esters following intravenous
administration of heparin.
serum decreased (Figure 2). In hyperlipemic
individuals the decrease in turbidity preceded the
onset of maximum clearing activity. Simultane-
ously with the increase in turbidity and the onset
of clearing activity, the blood levels of the neutral
fats (Figure 3), of the total cholesterol and
cholesterol esters (Figure 4), and of the phos-
pholipids (Figure 5) declined. In hyperlipemic
individuals, the decrease in the concentration
of the lipids was pronounced because of their
high initial levels. The maximum rate of decline
of the neutral fats preceded maximum clearing
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FIG. 5. Changes in the plasma phospholipid levels following intravenous administration of heparin.
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FIG. 6. Changes in plasma antilipolytic activity following intravenous administration of heparin.
activity. The lowest levels of neutral fat were
reached prior to those of cholesterol and phos-
pholipids and occurred at the time of maximum
clearing activity.
Within one minute following the adminis-
tration of intravenous heparin the serum of
normal individuals was found to inhibit clearing
activity and the serum of hyperlipemic patients
which was inhibitory even before the injection of
heparin became more markedly inhibitory. The
inhibitory activity disappeared rapidly from the
serum of normals, while it persisted in the serum
of patients with hyperlipemia (Figure 6). The
inhibitory activity in the serum of hyperlipemie
patients diminished over the next 3 to 4 hours as
their clearing activity increased; inhibition
reached a minimum when clearing activity was at
its highest level. The serum of the hyperlipemic
patients then gradually regained its inhibitory
activity. Antilipolytic activity returned to its
preheparin levels within 16 to 24 hours.
A questionable antilipolytic activity appeared
in the serum of normal individuals after oral fat
intake (Figure 7). The levels of antilipolytic
activity in the serum of hyperlipemic patients
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FIG. 7. Changes in plasma antilipolytic activity following ingestion of a fatty meal.
A, B,—hyperlipemic subjects; C, D,—normal subjects.
increased considerably after oral fat adminis-
tration.
DISCUSSION
The data presented here indicate considerable
differences both in vivo and in vitro in the effects
of heparin on the formation of lipemia clearing
activity in patients with hyperlipemia and in
normal subjects.
The previously reported defect (2) in the
lipemia clearing response of hyperlipemic patients
to heparin has been confirmed by the studies
presented here. The clearing activity induced by
heparin in patients with hyperlipemia is con-
siderably less than in normal individuals. Current
studies suggest that the hyperlipemic patient
produces more clearing factor than the normal
individual in response to an equivalent amount
of heparin (7). The relatively high levels of anti-
lipolytic activity in hyperlipemic serum, how-
ever, neutralize the action of the clearing factor,
resulting in a low net clearing activity. Thus it
appears that the delay in the appearance of
heparin-induced clearing activity in hyperlipemic
patients is associated with a time-consuming
compensatory increase in the evolution of clearing
factor.
It is evident that the decrease in optical density
following heparin administration is due only in
part to the removal of neutral fat from the blood
stream; previous ultracentrifugal studies (18), as
well as the present in vitro studies indicate that
transformation of the lipids and the lipoproteins
is, to a considerable extent, responsible for the
optical density changes since the concentration
of the total fatty acids as well as that of choles-
terol and phospholipids obviously remains un-
altered in the in vitro test system. This may ex-
plain why the optical density decreases prior to
the decline in the neutral fat levels of the blood
and why it remains low even after they have re-
turned to their pre-injection levels.
Changes in the lipoproteins were further indi-
cated by the electrophoretic studies. Electro-
phoresis disclosed an increase in the mobilities of
the alpha and beta lipoproteins in hyperlipemic
serum prior to the appearance of optical density
changes or evolution of glycerol. This suggests
that electrophoresis, as previously noted (2), is a
more sensitive method for the demonstration of
lipemia clearing activity than the other methods
employed here.
The glycerol levels increased as the optical
density changes and the rate of electrophoretic
migration of the lipoproteins increased and those
of the lipid levels declined. These studies, there-
fore, indicate that lipolysis and transformation
of the lipoproteins (18) are interrelated with the
elimination of fats from the blood stream.
Increased antilipolytic activity appears in the
serum of patients with hyperlipemia after oral
fat intake, whereas in normal serum with no
measurable antilipolytic activity before fat in-
take, little or no inhibition is found afterwards.
This difference between hyperlipemic patients
and normal individuals indicates that elevation
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of the lipid level alone does not result in increased
antilipolytic activity.
The lipemia clearing response to heparin of
hyperlipemic patients differs from that of normal
individuals primarily in degree. Hollett and
Meng (19) have demonstrated the presence of an
inhibitor of lipemia clearing in normal human
serum. The present as well as previous studies
(2, 3) indicate, however, that the levels of in-
lubitory activity in hyperlipemie serum greatly
exceed those in normal serum.
SUMMARY
1. Equivalent amounts of heparin induce less
clearing activity in patients with hyperlipemia
than in normal individuals. Development of
maximum levels of clearing activity is consider-
ably delayed in hyperlipemia.
2. The rate of eleetrophoretic migration of the
alpha and beta lipoproteins is increased immedi-
ately after the administration of heparin in
hyperlipemie patients as well as in normals. This
suggests that even in hyperlipemie individuals
some immediate clearing activity is present.
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DISCUSSION
DR. TREODOEE COENDLEET (Chicago, Illinois):
In their earlier experiments on the clearing
response to heparin, the essayists did not have
the opportunity to observe the effects of toluidine
blue, a heparin antagonist. Does toluidine blue
intensify lipemia in idiopathic hyperlipemia?
One may conceive of the toluidine blue fixing the
the mast cells. If, on the other hand, Idiopathic
Hyperlipemia is based on the relative absence of
heparin in the mast cells, then it would not be
expected that toluidine blue would intensify the
lipemia.
Dn. EARL G. MeNALL (Los Angeles, Calif.):
I would like to congratulate Dr. Klein for a most
heparin and preventing the latter's escape from interesting presentation. I am very interested in
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the various interactions of heparin because
heparin has been reported by other workers and
our own group to bind properdin.
There are quite a number of polysaccharides
derived from mammalian tissues and from plant
and bacterial sources which have been studied in
their infection-promoting and properdin binding
activities. Some of these polysaccharides also
have heparin-like activity. The most active poly-
saccharides which have heparin activity are
sulfated derivatives. Carrageenin which is a
sulfated polygalaeturonie acid derivative, sul-
fated dextran, sulfated amylose, and a sulfated
polysaceharide from seaweed-laminarin, all pro-
long blood clotting and have lipemia clearing
activity. It is apparent that the clearing activities
of heparinoids depend on their ultimately causing
a release of esterases into serum. And these
esterases, by hydrolyzing chylomicrons, produce
clearing of lipemie sera. It is to be hoped that
clinically suitable, chemically descript poly-
saccharides may someday replace heparin which
must be purified from animal tissues since
varying molecular weight classes of this polymer
as well as its chemical make up vary slightly
depending upon the organ and species from which
the heparin is prepared.
Dn. EDMUND KLEIN (in closing): In answer to
Dr. Cornbleet's question, there is no evidence
that toluidine blue inhibits lipemia clearing by
direct complex formation with clearing factor.
With regard to Dr. McNall's point, the acti-
vating effects on the system are not confined to
polysaccharides, and can be demonstrated with
a number of other materials.
